Our recent activity
Asabys announces the first close of its fund, with commitments of €100M, and appoints Sylvain Sachot and Guillem Masferrer as partners
Asabys has announced the 1st closing of its 2nd fund, with commitments of €100 million. The firm’s goal is to reach €200 million this year, to invest in 12 to 15 companies in the EU, Israel, UK and the US.
Banco Sabadell stands as the firm’s main private institutional investor, like in its previous fund in 2018. Other Investors include the European Investment Fund and Alantra.
The fund will invest health technologies across the board, including biopharma, medical devices, and digital health companies, developing novel solutions based in solid scientific evidence with the aim to improve patients’ outcomes.
Asabys has announced today the 1st closing of its new fund, Sabadell Asabys Health Innovation Investments II (SAHII II), with total commitments of 100 million euros, expecting to reach a size of €200 million this year. SAHII II will invest in healthtech and biopharma companies, that provide novel solutions to unmet medical needs, with solid scientific evidence, and a clear benefit for patients.
This new fund consolidates Asabys launch back in 2018, investing mainly in the EU, UK, Israel and the US, with a special focus in Spain, and corroborates the market interest for Asabys’ hybrid investment model, that ranges from biopharmaceutical projects to digital solutions, including advanced diagnostic tools and medical devices. Asabys announces this first closing only 6 months after the launch of the fund.
Clara Campas comments “After 4 years since launch, this first closing consolidates us as a firm, and reaffirms investors’ growing interest for private investment in healthcare”.
Josep Ll. Sanfeliu adds “This new fund represents a consolidation of our investment strategy, aimed at exceeding €500 million in assets under management in the coming years, with the aim of transforming the cutting-edge science of our research centers into disruptive and effective solutions, facing the challenges that we currently have in areas such as oncology, neurology and cardiovascular”.
Asabys has reinforced its team of professionals with new incorporations and has appointed Sylvain Sachot and Guillem Masferrer as partners, both with extensive experience as venture capital investors in the life sciences and healthcare industries, who have been part of the firm since inception.
Sylvain Sachot has a PhD in Molecular Biology from the University of Nantes and an MBA from ESADE. He worked for a decade in academic laboratories such as INSERM (France) and the Mount Sinai School of Medicine (New York), researching in the field of gene therapy and regenerative medicine. Sylvain has an extensive experience in venture capital, having invested in Biotech and MedTech companies worldwide.
Guillem Masferrer, BsC in Business Administration by UPF, has 8 years of experience in healthcare venture capital. Guillem has led the construction of Asabys’ digital health portfolio, currently comprised by 4 companies, helping position the firm as one of the leading European investors in digital health.
About Asabys Partners
Asabys Partners is a venture capital firm specialized in the healthcare sector, founded by Josep Ll. Sanfeliu and Clara Campàs and participated by Alantra. With close to €217 million in AUM and 13 portfolio companies (+1 exit), Asabys invests in highly innovative and disruptive companies covering unmet medical needs in the biopharma and healthtech verticals. Asabys has the backing of Banco Sabadell as anchor investor. https://asabys.com/
Ona Therapeutics, a portfolio company of Asabys Partners and Alta Life Sciences, appoints Dr. Antoine Yver as Chair of the Board to accelerate its ADC programs towards clinical development
Ona Therapeutics, a portfolio company of Asabys Partners and Alta Life Sciences, appoints Dr. Antoine Yver as Chair of the Board to accelerate its ADC programs towards clinical development
AltamarCAM and Asabys agree to integrate Aliath, their life sciences unit, into Asabys
AltamarCAM and Asabys agree to integrate Aliath, their life sciences unit, into Asabys
Asabys Partners Leads €10 Million Extension of SafeHeal’s Oversubscribed Series C Financing to Accelerate Commercialization of Colovac®